Stocks · News reference

Humacyte Confirms Plans For ATEV Supplemental BLA Filing

Aug 24, 2026, 12:03 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 24, 2026, 12:03 PM
Checked: Aug 24, 2026, 1:28 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 15, 2026, 3:35 PMBenzinga Newsdesk
Humacyte shares are trading higher after the company reported a 44% increase in the number of hospitals ordering Symvess in Q3 2026.
HUMA
BenzingaOct 15, 2026, 1:18 PMBenzinga Newsdesk
Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026
HUMA
BenzingaOct 12, 2026, 12:03 PMBenzinga Newsdesk
Humacyte Says Interim Phase 3 Data For ATEV In Dialysis Access To Be Presented October 22, sBLA Filing Expected This Quarter
HUMA
BenzingaOct 7, 2026, 12:45 PMBenzinga Newsdesk
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5
Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.
HUMA